Galectin Therapeutics Inc. Stock
Galectin Therapeutics Inc. Stock price
Key metrics
| Market capitalization | $82.91m |
| Enterprise Value | $107.57m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | negative |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-40.68m |
| Free Cash Flow (TTM) Free Cash Flow | $-37.35m |
| Cash position | $7.43m |
Is Galectin Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
Galectin Therapeutics Inc. Stock Analysis
Analyst Opinions
1 Analyst has issued a forecast Galectin Therapeutics Inc.:
Analyst Opinions
1 Analyst has issued a forecast Galectin Therapeutics Inc.:
Financial data from Galectin Therapeutics Inc.
| Mar '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -41 -41 |
-
|
EBIT (Operating Income) EBIT | -41 -41 |
9%
9%
|
| Net Profit | -45 -45 |
1%
1%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Galectin Therapeutics Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galectin Therapeutics Inc. Stock News
Company Profile
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease and cancer. Its programs target the development of carbohydrate molecules which offers offer alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
| Head office | United States |
| CEO | Joel Lewis |
| Employees | 15 |
| Founded | 2000 |
| Website | galectintherapeutics.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
